ангиотензин 1-7 在白色脂肪组织中的抗炎作用
Nozomi Nishida1, Satoru Sugimoto1, Satoshi Miyagaki1
1Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Adipocyte
|January 13, 2025
概括
ангиотензин 1-7 (Ang 1-7) 降低了肥胖小鼠白脂肪组织 (WAT) 的炎症. 这种可以缓解肥胖引起的炎症,并通过向关键炎症标志物来改善胰岛素抵抗.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 代谢研究研究 代谢研究
背景情况:
- 肥胖是一个全球性健康问题,与慢性炎症和胰岛素抵抗有关.
- 氨酸-1-7 (Ang 1-7) 的氨酸-氨酸系统 (RAS) 显示在肥胖中具有抗炎功能,但机制尚不清楚.
- 白色脂肪组织 (WAT) 的炎症由MCP-1和TNF-α等细胞因子驱动,加剧代谢功能障碍.
研究的目的:
- 为了研究Ang 1-7对饮食诱导的肥胖小鼠白脂肪组织 (WAT) 炎症的影响.
- 阐明Ang 1-7调节肥胖相关炎症的分子机制.
- 在肥胖的背景下,评估Ang 1-7对胰岛素耐药性的影响.
主要方法:
- 在小鼠中饮食诱导的肥胖模型.
- 基因表达 (MCP-1,TNF-α) 和组织学标记物 (冠状结构) 在内脏外皮膜WAT (eWAT) 中的分析.
- 测量循环中的MCP-1和TNF-α水平,评估胰岛素耐药性.
- 在体外研究中使用3T3-L1脂肪细胞和RAW 264.7巨细胞来评估细胞因子分泌.
主要成果:
- 在肥胖小鼠的eWAT中,Ang 1-7显著降低了MCP-1和TNF-α基因表达和冠状结构.
- 循环中的MCP-1和TNF-α水平降低了Ang1-7,与改善的胰岛素抵抗相关.
- 在体外,Ang 1-7抑制了脂肪细胞的MCP-1分泌和巨细胞的TNF-α分泌.
- Ang 1-7对WAT和相关免疫细胞表现出直接的抗炎作用.
结论:
- Ang 1-7 直接减轻白色脂肪组织 (WAT) 中肥胖引起的炎症.
- 该可以降低脂肪组织和血液循环中的关键的促炎细胞因子 (MCP-1,TNF-α).
- Ang 1-7 治疗改善了肥胖小鼠的胰岛素抵抗,这表明了治疗潜力.
- 这项研究为Ang 1-7的抗肥胖作用提供了新的机制性见解.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
470
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
470
Antihypertensive Drugs: Angiotensin II Receptor Blockers
578
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
578
Antihypertensive Drugs: Direct Renin Inhibitors
483
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
483
Adrenergic Receptors: β Subtype
1.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K


